share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K:重大事件
美股SEC公告 ·  2024/06/08 04:03

Moomoo AI 已提取核心信息

TransCode Therapeutics announced on June 3, 2024, that it has successfully regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The company now meets all applicable listing standards for continued listing on The Nasdaq Capital Market, resulting in the cancellation of the previously scheduled Nasdaq Hearings Panel hearing set for June 25, 2024.The company remains under mandatory panel monitoring as defined in Nasdaq Listing Rule 5815(d)(4)(B) through January 27, 2025, ensuring ongoing compliance with listing requirements.
TransCode Therapeutics announced on June 3, 2024, that it has successfully regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The company now meets all applicable listing standards for continued listing on The Nasdaq Capital Market, resulting in the cancellation of the previously scheduled Nasdaq Hearings Panel hearing set for June 25, 2024.The company remains under mandatory panel monitoring as defined in Nasdaq Listing Rule 5815(d)(4)(B) through January 27, 2025, ensuring ongoing compliance with listing requirements.
TransCode Therapeutics, Inc.于2024年6月3日宣布,其已收到纳斯达克总法律顾问办公室的通知,确认公司符合继续在纳斯达克资本市场上市的最低买盘要求。由于重新符合要求,原定于2024年6月25日召开的纳斯达克听证会已被取消。然而,根据纳斯达克上市规则5815(d)(4)(B)条款,该公司将继续遵守强制性的小组监控,直到2025年1月27日。这一进展是针对TransCode遵守纳斯达克上市标准方面之前的担忧。
TransCode Therapeutics, Inc.于2024年6月3日宣布,其已收到纳斯达克总法律顾问办公室的通知,确认公司符合继续在纳斯达克资本市场上市的最低买盘要求。由于重新符合要求,原定于2024年6月25日召开的纳斯达克听证会已被取消。然而,根据纳斯达克上市规则5815(d)(4)(B)条款,该公司将继续遵守强制性的小组监控,直到2025年1月27日。这一进展是针对TransCode遵守纳斯达克上市标准方面之前的担忧。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息